Alto Begin Period Cash Flow from 2010 to 2024
| ANRO Stock | 4.38 0.03 0.68% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 55.6 M | Current Value 28.6 M | Quarterly Volatility 17.6 M |
Check Alto Neuroscience, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alto Neuroscience,'s main balance sheet or income statement drivers, such as Net Interest Income of 1.2 M, Interest Income of 2.8 M or Depreciation And Amortization of 315.3 K, as well as many indicators such as Price To Sales Ratio of 2 K, Dividend Yield of 0.0 or Days Sales Outstanding of 2.4 K. Alto financial statements analysis is a perfect complement when working with Alto Neuroscience, Valuation or Volatility modules.
Alto | Begin Period Cash Flow |
Latest Alto Neuroscience,'s Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Alto Neuroscience, over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Alto Neuroscience,'s Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alto Neuroscience,'s overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Alto Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 13,490,991 | |
| Geometric Mean | 7,277,224 | |
| Coefficient Of Variation | 130.73 | |
| Mean Deviation | 13,906,920 | |
| Median | 4,009,000 | |
| Standard Deviation | 17,636,462 | |
| Sample Variance | 311T | |
| Range | 51.6M | |
| R-Value | 0.72 | |
| Mean Square Error | 163.4T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 2,822,373 | |
| Total Sum of Squares | 4354.6T |
Alto Begin Period Cash Flow History
About Alto Neuroscience, Financial Statements
Alto Neuroscience, investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Alto Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 55.6 M | 28.6 M |
Pair Trading with Alto Neuroscience,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will appreciate offsetting losses from the drop in the long position's value.Moving against Alto Stock
| 0.87 | ELDN | Eledon Pharmaceuticals Downward Rally | PairCorr |
| 0.75 | VRNA | Verona Pharma PLC | PairCorr |
| 0.73 | ETON | Eton Pharmaceuticals | PairCorr |
| 0.62 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.42 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Alto Neuroscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience, to buy it.
The correlation of Alto Neuroscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Alto Neuroscience, Correlation against competitors. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.38) | Return On Assets (0.32) | Return On Equity (0.57) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.